In the last 12 months, insiders at Schrodinger, Inc. ($SDGR) filed 191 transactions with the SEC: 0 open-market purchases totaling $0 and 39 sales totaling $5,970,169. Net insider sentiment: net selling.
Schrodinger, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Tran Yvonne (EVP, CLO & CPO) — 24 transactions totaling $1,942,969
- Farid Ramy (President & CEO) — 16 transactions totaling $1,416,333
- Lorton Kenneth Patrick (EVP & Chief Technology Officer) — 4 transactions totaling $801,229
- Tran Yvonne (EVP & Chief Legal Officer) — 7 transactions totaling $756,376
- Thornberry Nancy (Director) — 9 transactions totaling $690,822
View all SEC Filings for Schrodinger, Inc. (SDGR).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Jain Rachit | EVP & CFO | S | Common Stock | 1631 | $12.90 | 52,596.0000 | 73,613,090 | 3.01% | 0.00% |
| March 5, 2026 | Herman Jenny | CAO | S | Common Stock | 775 | $12.85 | 35,412.0000 | 73,613,090 | 2.14% | 0.00% |
| March 6, 2026 | Herman Jenny | CAO | S | Common Stock | 608 | $12.84 | 34,804.0000 | 73,613,090 | 1.72% | 0.00% |
| March 5, 2026 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 1094 | $12.90 | 52,683.0000 | 73,613,090 | 2.03% | 0.00% |
| March 5, 2026 | Farid Ramy | President & CEO | S | Common Stock | 3661 | $12.91 | 330,824.0000 | 73,613,090 | 1.09% | 0.00% |
| March 5, 2026 | Akinsanya Karen | See Remarks | S | Common Stock | 1366 | $12.90 | 69,956.0000 | 73,613,090 | 1.92% | 0.00% |
| March 5, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | S | Common Stock | 1222 | $12.90 | 89,241.0000 | 73,613,090 | 1.35% | 0.00% |
| March 4, 2026 | Abel Robert Lorne | See Remarks | S | Common Stock | 1300 | $12.81 | 55,897.0000 | 73,613,090 | 2.27% | 0.00% |
| March 2, 2026 | Friesner Richard | Director | M | Stock Option (right to buy) | 160527 | $0.00 | 0.0000 | 73,613,090 | 100.00% | 0.22% |
| March 2, 2026 | Friesner Richard | Director | M | Common Stock | 160527 | $3.07 | 1,405,477.0000 | 73,613,090 | 12.89% | 0.22% |
| March 2, 2026 | Aklian Mannix Vartan | See Remarks | A | Stock Option (right to buy) | 34250 | $0.00 | 34,250.0000 | 73,613,090 | 9999.99% | 0.05% |
| March 2, 2026 | Aklian Mannix Vartan | See Remarks | A | Common Stock | 17130 | $0.00 | 31,193.0000 | 73,613,090 | 121.81% | 0.02% |
| March 2, 2026 | Jain Rachit | EVP & CFO | A | Stock Option (right to buy) | 34250 | $0.00 | 34,250.0000 | 73,613,090 | 9999.99% | 0.05% |
| March 2, 2026 | Jain Rachit | EVP & CFO | A | Common Stock | 17130 | $0.00 | 54,227.0000 | 73,613,090 | 46.18% | 0.02% |
| March 2, 2026 | Tran Yvonne | EVP, CLO & CPO | A | Stock Option (right to buy) | 34250 | $0.00 | 34,250.0000 | 73,613,090 | 9999.99% | 0.05% |
| March 2, 2026 | Tran Yvonne | EVP, CLO & CPO | A | Common Stock | 13788 | $0.00 | 53,777.0000 | 73,613,090 | 34.48% | 0.02% |
| March 2, 2026 | Tran Yvonne | EVP, CLO & CPO | A | Common Stock | 17130 | $0.00 | 39,989.0000 | 73,613,090 | 74.94% | 0.02% |
| March 2, 2026 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 112500 | $0.00 | 112,500.0000 | 73,613,090 | 9999.99% | 0.15% |
| March 2, 2026 | Farid Ramy | President & CEO | S | Common Stock | 5560 | $11.90 | 334,485.0000 | 73,613,090 | 1.64% | 0.01% |
| March 2, 2026 | Farid Ramy | President & CEO | A | Common Stock | 48259 | $0.00 | 340,045.0000 | 73,613,090 | 16.54% | 0.07% |
| March 2, 2026 | Farid Ramy | President & CEO | A | Common Stock | 13604 | $0.00 | 291,786.0000 | 73,613,090 | 4.89% | 0.02% |
| March 2, 2026 | Farid Ramy | President & CEO | A | Common Stock | 56250 | $0.00 | 278,182.0000 | 73,613,090 | 25.35% | 0.08% |
| March 2, 2026 | Abel Robert Lorne | See Remarks | A | Stock Option (right to buy) | 34250 | $0.00 | 34,250.0000 | 73,613,090 | 9999.99% | 0.05% |
| March 2, 2026 | Abel Robert Lorne | See Remarks | A | Common Stock | 20682 | $0.00 | 57,197.0000 | 73,613,090 | 56.64% | 0.03% |
| March 2, 2026 | Abel Robert Lorne | See Remarks | A | Common Stock | 17130 | $0.00 | 36,515.0000 | 73,613,090 | 88.37% | 0.02% |
| March 2, 2026 | Akinsanya Karen | See Remarks | A | Stock Option (right to buy) | 48500 | $0.00 | 48,500.0000 | 73,613,090 | 9999.99% | 0.07% |
| March 2, 2026 | Akinsanya Karen | See Remarks | S | Common Stock | 2206 | $11.99 | 71,322.0000 | 73,613,090 | 3.00% | 0.00% |
| March 2, 2026 | Akinsanya Karen | See Remarks | A | Common Stock | 27576 | $0.00 | 73,528.0000 | 73,613,090 | 60.01% | 0.04% |
| March 2, 2026 | Akinsanya Karen | See Remarks | A | Common Stock | 6077 | $0.00 | 45,952.0000 | 73,613,090 | 15.24% | 0.01% |
| March 2, 2026 | Akinsanya Karen | See Remarks | A | Common Stock | 24250 | $0.00 | 39,875.0000 | 73,613,090 | 155.20% | 0.03% |
| March 2, 2026 | Herman Jenny | CAO | A | Stock Option (right to buy) | 8220 | $0.00 | 8,220.0000 | 73,613,090 | 9999.99% | 0.01% |
| March 2, 2026 | Herman Jenny | CAO | A | Common Stock | 9590 | $0.00 | 36,187.0000 | 73,613,090 | 36.06% | 0.01% |
| March 2, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Stock Option (right to buy) | 34250 | $0.00 | 34,250.0000 | 73,613,090 | 9999.99% | 0.05% |
| March 2, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Common Stock | 20682 | $0.00 | 90,463.0000 | 73,613,090 | 29.64% | 0.03% |
| March 2, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Common Stock | 17130 | $0.00 | 69,781.0000 | 73,613,090 | 32.53% | 0.02% |
| Feb. 10, 2026 | Herman Jenny | CAO | S | Common Stock | 752 | $13.79 | 26,597.0000 | 73,613,090 | 2.75% | 0.00% |
| Feb. 10, 2026 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | S | Common Stock | 925 | $13.73 | 52,651.0000 | 73,613,090 | 1.73% | 0.00% |
| Feb. 10, 2026 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 776 | $13.80 | 22,859.0000 | 73,613,090 | 3.28% | 0.00% |
| Feb. 9, 2026 | Abel Robert Lorne | See Remarks | S | Common Stock | 1230 | $13.51 | 19,385.0000 | 73,613,090 | 5.97% | 0.00% |
| Oct. 16, 2025 | Dugan Margaret | Chief Medical Officer | S | Common Stock | 1395 | $21.07 | 24,574.0000 | 73,613,090 | 5.37% | 0.00% |
| June 18, 2025 | van Kralingen Bridget A | Director | A | Stock Option (right to buy) | 2335 | $0.00 | 2,335.0000 | 72,670,295 | 9999.99% | 0.00% |
| June 18, 2025 | Thornberry Nancy | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | Thornberry Nancy | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | Kapeller-Libermann Rosana | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | Kapeller-Libermann Rosana | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | GINSBERG GARY L | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | GINSBERG GARY L | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | OBEROI ARUN | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | OBEROI ARUN | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | Friesner Richard | Director | A | Common Stock | 5997 | $0.00 | 1,244,950.0000 | 72,670,295 | 0.48% | 0.01% |
| June 18, 2025 | Friesner Richard | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | Sender Gary | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | Sender Gary | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | Lynton Michael | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | Lynton Michael | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| June 18, 2025 | van Kralingen Bridget A | Director | A | Common Stock | 1499 | $0.00 | 11,499.0000 | 72,670,295 | 14.99% | 0.00% |
| June 18, 2025 | Chodakewitz Jeffrey | Director | A | Common Stock | 5997 | $0.00 | 17,247.0000 | 72,670,295 | 53.31% | 0.01% |
| June 18, 2025 | Chodakewitz Jeffrey | Director | A | Stock Option (right to buy) | 9341 | $0.00 | 9,341.0000 | 72,670,295 | 9999.99% | 0.01% |
| May 29, 2025 | Aklian Mannix Vartan | See Remarks | A | Stock Option (right to buy) | 84375 | $0.00 | 84,375.0000 | 72,670,295 | 9999.99% | 0.12% |
| May 29, 2025 | Aklian Mannix Vartan | See Remarks | A | Common Stock | 14063 | $0.00 | 14,063.0000 | 72,670,295 | 9999.99% | 0.02% |
| May 21, 2025 | Jain Rachit | EVP & CFO | A | Common Stock | 9375 | $0.00 | 37,097.0000 | 72,670,295 | 33.82% | 0.01% |
| May 21, 2025 | Jain Rachit | EVP & CFO | A | Stock Option (right to buy) | 18750 | $0.00 | 18,750.0000 | 72,670,295 | 9999.99% | 0.03% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | S | Common Stock | 8378 | $25.11 | 23,970.0000 | 72,670,295 | 25.90% | 0.01% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | S | Common Stock | 5000 | $25.11 | 18,970.0000 | 72,670,295 | 20.86% | 0.01% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | S | Common Stock | 3345 | $25.00 | 15,625.0000 | 72,670,295 | 17.63% | 0.00% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | M | Stock Option (right to buy) | 13378 | $0.00 | 0.0000 | 72,670,295 | 100.00% | 0.02% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | M | Stock Option (right to buy) | 3345 | $0.00 | 0.0000 | 72,670,295 | 100.00% | 0.00% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | M | Common Stock | 3345 | $2.92 | 32,348.0000 | 72,670,295 | 11.53% | 0.00% |
| April 14, 2025 | Akinsanya Karen | President of R&D, Therapeutics | M | Common Stock | 13378 | $3.22 | 29,003.0000 | 72,670,295 | 85.62% | 0.02% |
| March 7, 2025 | van Kralingen Bridget A | Director | A | Common Stock | 10000 | $0.00 | 10,000.0000 | 72,670,295 | 9999.99% | 0.01% |
| March 7, 2025 | van Kralingen Bridget A | Director | A | Stock Option (right to buy) | 17050 | $0.00 | 17,050.0000 | 72,670,295 | 9999.99% | 0.02% |
| March 6, 2025 | Herman Jenny | SVP & Controller | S | Common Stock | 666 | $21.11 | 27,349.0000 | 72,670,295 | 2.38% | 0.00% |
| March 3, 2025 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Common Stock | 12500 | $0.00 | 53,576.0000 | 72,670,295 | 30.43% | 0.02% |
| March 3, 2025 | Porges Geoffrey Craig | EVP & CFO | A | Common Stock | 12500 | $0.00 | 18,185.0000 | 72,670,295 | 219.88% | 0.02% |
| March 3, 2025 | Porges Geoffrey Craig | EVP & CFO | A | Common Stock | 14850 | $0.00 | 33,035.0000 | 72,670,295 | 81.66% | 0.02% |
| March 3, 2025 | Porges Geoffrey Craig | EVP & CFO | S | Common Stock | 5491 | $21.76 | 27,544.0000 | 72,670,295 | 16.62% | 0.01% |
| March 3, 2025 | Porges Geoffrey Craig | EVP & CFO | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 72,670,295 | 9999.99% | 0.07% |
| March 3, 2025 | Akinsanya Karen | President of R&D, Therapeutics | A | Common Stock | 15625 | $0.00 | 15,625.0000 | 72,670,295 | 9999.99% | 0.02% |
| March 3, 2025 | Akinsanya Karen | President of R&D, Therapeutics | A | Stock Option (right to buy) | 62500 | $0.00 | 62,500.0000 | 72,670,295 | 9999.99% | 0.09% |
| March 3, 2025 | Farid Ramy | President & CEO | A | Common Stock | 37500 | $0.00 | 221,932.0000 | 72,670,295 | 20.33% | 0.05% |
| March 3, 2025 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 72,670,295 | 9999.99% | 0.08% |
| March 3, 2025 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 72,670,295 | 9999.99% | 0.12% |
| March 3, 2025 | Dugan Margaret | Chief Medical Officer | A | Common Stock | 12500 | $0.00 | 25,969.0000 | 72,670,295 | 92.81% | 0.02% |
| March 3, 2025 | Dugan Margaret | Chief Medical Officer | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 72,670,295 | 9999.99% | 0.07% |
| March 3, 2025 | Herman Jenny | SVP & Controller | A | Common Stock | 9800 | $0.00 | 28,015.0000 | 72,670,295 | 53.80% | 0.01% |
| March 3, 2025 | Herman Jenny | SVP & Controller | A | Stock Option (right to buy) | 8400 | $0.00 | 8,400.0000 | 72,670,295 | 9999.99% | 0.01% |
| March 3, 2025 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 72,670,295 | 9999.99% | 0.07% |
| March 3, 2025 | Tran Yvonne | EVP, CLO & CPO | A | Common Stock | 12500 | $0.00 | 23,635.0000 | 72,670,295 | 112.26% | 0.02% |
| March 3, 2025 | Tran Yvonne | EVP, CLO & CPO | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 72,670,295 | 9999.99% | 0.07% |
| March 3, 2025 | Abel Robert Lorne | See Remarks | A | Common Stock | 12500 | $0.00 | 20,615.0000 | 72,670,295 | 154.04% | 0.02% |
| March 3, 2025 | Abel Robert Lorne | See Remarks | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 72,670,295 | 9999.99% | 0.07% |
| Feb. 18, 2025 | Tran Yvonne | EVP, CLO & CPO | M | Stock Option (right to buy) | 3902 | $0.00 | 0.0000 | 72,670,295 | 100.00% | 0.01% |
| Feb. 18, 2025 | Tran Yvonne | EVP, CLO & CPO | M | Common Stock | 3902 | $4.34 | 15,037.0000 | 72,670,295 | 35.04% | 0.01% |
| Feb. 18, 2025 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 3902 | $28.00 | 11,135.0000 | 72,670,295 | 25.95% | 0.01% |
| Feb. 10, 2025 | Abel Robert Lorne | See Remarks | S | Common Stock | 1225 | $25.99 | 8,115.0000 | 72,670,295 | 13.12% | 0.00% |
| Feb. 11, 2025 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | S | Common Stock | 985 | $24.43 | 41,076.0000 | 72,670,295 | 2.34% | 0.00% |
| Feb. 11, 2025 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 828 | $24.43 | 11,135.0000 | 72,670,295 | 6.92% | 0.00% |
| Feb. 11, 2025 | Herman Jenny | SVP & Controller | S | Common Stock | 859 | $24.43 | 18,215.0000 | 72,670,295 | 4.50% | 0.00% |
| Oct. 15, 2024 | Dugan Margaret | Chief Medical Officer | S | Common Stock | 1531 | $17.78 | 13,469.0000 | 72,813,006 | 10.21% | 0.00% |
| June 18, 2024 | Thornberry Nancy | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | Lynton Michael | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | OBEROI ARUN | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | Sender Gary | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | Sender Gary | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | Thornberry Nancy | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | GINSBERG GARY L | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | GINSBERG GARY L | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | Friesner Richard | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | Friesner Richard | Director | A | Common Stock | 5000 | $0.00 | 1,238,953.0000 | 74,986,816 | 0.41% | 0.01% |
| June 18, 2024 | Kapeller-Libermann Rosana | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | Kapeller-Libermann Rosana | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | Lynton Michael | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | OBEROI ARUN | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| June 18, 2024 | Chodakewitz Jeffrey | Director | A | Common Stock | 5000 | $0.00 | 11,250.0000 | 74,986,816 | 80.00% | 0.01% |
| June 18, 2024 | Chodakewitz Jeffrey | Director | A | Stock Option (right to buy) | 8550 | $0.00 | 8,550.0000 | 74,986,816 | 9999.99% | 0.01% |
| March 21, 2024 | Abel Robert Lorne | See Remarks | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 74,986,816 | 9999.99% | 0.04% |
| March 21, 2024 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 74,986,816 | 9999.99% | 0.04% |
| March 6, 2024 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | M | Common Stock | 5574 | $4.34 | 42,061.0000 | 74,986,816 | 15.28% | 0.01% |
| March 6, 2024 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | M | Stock Option (right to buy) | 5574 | $0.00 | 0.0000 | 74,986,816 | 100.00% | 0.01% |
| March 4, 2024 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 74,986,816 | 9999.99% | 0.08% |
| March 4, 2024 | Tran Yvonne | EVP, CLO & CPO | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 74,986,816 | 9999.99% | 0.08% |
| March 4, 2024 | Dugan Margaret | Chief Medical Officer | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 74,986,816 | 9999.99% | 0.08% |
| March 4, 2024 | Abel Robert Lorne | See Remarks | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 74,986,816 | 9999.99% | 0.08% |
| March 4, 2024 | Porges Geoffrey Craig | EVP & CFO | A | Common Stock | 9000 | $0.00 | 9,000.0000 | 74,986,816 | 9999.99% | 0.01% |
| March 4, 2024 | Porges Geoffrey Craig | EVP & CFO | S | Common Stock | 3315 | $26.35 | 5,685.0000 | 74,986,816 | 36.83% | 0.00% |
| March 4, 2024 | Porges Geoffrey Craig | EVP & CFO | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 74,986,816 | 9999.99% | 0.12% |
| March 4, 2024 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 126000 | $0.00 | 126,000.0000 | 74,986,816 | 9999.99% | 0.17% |
| March 4, 2024 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 87271 | $0.00 | 87,271.0000 | 74,986,816 | 9999.99% | 0.12% |
| March 4, 2024 | Herman Jenny | SVP & Controller | A | Common Stock | 7313 | $0.00 | 19,074.0000 | 74,986,816 | 62.18% | 0.01% |
| March 4, 2024 | Herman Jenny | SVP & Controller | A | Stock Option (right to buy) | 14625 | $0.00 | 14,625.0000 | 74,986,816 | 9999.99% | 0.02% |
| March 4, 2024 | Akinsanya Karen | President of R&D, Therapeutics | A | Stock Option (right to buy) | 120000 | $0.00 | 120,000.0000 | 74,986,816 | 9999.99% | 0.16% |
| Feb. 12, 2024 | Lorton Kenneth Patrick | EVP, CTO & COO, Software | S | Common Stock | 901 | $28.29 | 36,487.0000 | 74,986,816 | 2.41% | 0.00% |
| Feb. 12, 2024 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 758 | $28.29 | 11,963.0000 | 74,986,816 | 5.96% | 0.00% |
| Feb. 12, 2024 | Herman Jenny | SVP & Controller | S | Common Stock | 787 | $28.29 | 11,761.0000 | 74,986,816 | 6.27% | 0.00% |
| Feb. 12, 2024 | Abel Robert Lorne | See Remarks | S | Common Stock | 1205 | $27.55 | 9,340.0000 | 74,986,816 | 11.43% | 0.00% |
| Sept. 15, 2023 | Herman Jenny | SVP & Controller | M | Common Stock | 4545 | $1.20 | 12,548.0000 | 71,173,419 | 56.79% | 0.01% |
| Sept. 15, 2023 | Herman Jenny | SVP & Controller | M | Stock Option (right to buy) | 4545 | $0.00 | 0.0000 | 71,173,419 | 100.00% | 0.01% |
| Aug. 9, 2023 | Dugan Margaret | Chief Medical Officer | A | Common Stock | 15000 | $0.00 | 15,000.0000 | 71,173,419 | 9999.99% | 0.02% |
| Aug. 9, 2023 | Lorton Kenneth Patrick | EVP & Chief Technology Officer | S | Common Stock | 10000 | $40.06 | 37,388.0000 | 71,173,419 | 21.10% | 0.01% |
| Aug. 9, 2023 | Dugan Margaret | Chief Medical Officer | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 71,173,419 | 9999.99% | 0.13% |
| June 30, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Stock Option (right to buy) | 12040 | $0.00 | 188,619.0000 | 71,173,419 | 6.00% | 0.02% |
| June 30, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Common Stock | 12040 | $17.00 | 24,761.0000 | 71,173,419 | 94.65% | 0.02% |
| June 30, 2023 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 12040 | $50.00 | 12,721.0000 | 71,173,419 | 48.62% | 0.02% |
| June 15, 2023 | Lynton Michael | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | Thornberry Nancy | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| June 15, 2023 | Thornberry Nancy | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | Chodakewitz Jeffrey | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| June 15, 2023 | Chodakewitz Jeffrey | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | Kapeller-Libermann Rosana | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| June 15, 2023 | Kapeller-Libermann Rosana | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | GINSBERG GARY L | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| June 15, 2023 | GINSBERG GARY L | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | Friesner Richard | Director | A | Common Stock | 6250 | $0.00 | 1,233,953.0000 | 71,173,419 | 0.51% | 0.01% |
| June 15, 2023 | Friesner Richard | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | Sender Gary | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| June 15, 2023 | Sender Gary | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | OBEROI ARUN | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| June 15, 2023 | OBEROI ARUN | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 71,173,419 | 9999.99% | 0.02% |
| June 15, 2023 | Lynton Michael | Director | A | Common Stock | 6250 | $0.00 | 6,250.0000 | 71,173,419 | 9999.99% | 0.01% |
| May 22, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Common Stock | 14892 | $4.34 | 27,721.0000 | 71,173,419 | 116.08% | 0.02% |
| May 23, 2023 | Lorton Kenneth Patrick | EVP & Chief Technology Officer | S | Common Stock | 10000 | $40.06 | 47,388.0000 | 71,173,419 | 17.43% | 0.01% |
| May 23, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Stock Option (right to buy) | 7960 | $4.34 | 3,902.0000 | 71,173,419 | 67.11% | 0.01% |
| May 22, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Stock Option (right to buy) | 14892 | $4.34 | 11,862.0000 | 71,173,419 | 55.66% | 0.02% |
| May 22, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Stock Option (right to buy) | 108 | $3.07 | 0.0000 | 71,173,419 | 100.00% | 0.00% |
| May 23, 2023 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 7960 | $40.01 | 12,721.0000 | 71,173,419 | 38.49% | 0.01% |
| May 23, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Common Stock | 7960 | $4.34 | 20,681.0000 | 71,173,419 | 62.57% | 0.01% |
| May 22, 2023 | Tran Yvonne | EVP, CLO & CPO | S | Common Stock | 15000 | $35.04 | 12,721.0000 | 71,173,419 | 54.11% | 0.02% |
| May 22, 2023 | Tran Yvonne | EVP, CLO & CPO | M | Common Stock | 108 | $3.07 | 12,829.0000 | 71,173,419 | 0.85% | 0.00% |
| May 22, 2023 | Thornberry Nancy | Director | M | Common Stock | 14850 | $11.52 | 14,850.0000 | 71,173,419 | 9999.99% | 0.02% |
| May 22, 2023 | Thornberry Nancy | Director | M | Stock Option (right to buy) | 14850 | $0.00 | 27,020.0000 | 71,173,419 | 35.47% | 0.02% |
| May 22, 2023 | Thornberry Nancy | Director | S | Common Stock | 14850 | $35.00 | 0.0000 | 71,173,419 | 100.00% | 0.02% |
| Feb. 9, 2023 | Porges Geoffrey Craig | EVP & CFO | A | Stock Option (right to buy) | 54735 | $0.00 | 54,735.0000 | 71,173,419 | 9999.99% | 0.08% |
| Feb. 9, 2023 | Tran Yvonne | EVP & Chief Legal Officer | A | Stock Option (right to buy) | 45525 | $0.00 | 45,525.0000 | 71,173,419 | 9999.99% | 0.06% |
| Feb. 9, 2023 | Tran Yvonne | EVP & Chief Legal Officer | A | Common Stock | 7590 | $0.00 | 12,721.0000 | 71,173,419 | 147.92% | 0.01% |
| Feb. 9, 2023 | Abel Robert Lorne | See Remarks | A | Stock Option (right to buy) | 63270 | $0.00 | 63,270.0000 | 71,173,419 | 9999.99% | 0.09% |
| Feb. 9, 2023 | Lorton Kenneth Patrick | EVP & Chief Technology Officer | A | Common Stock | 8170 | $0.00 | 57,388.0000 | 71,173,419 | 16.60% | 0.01% |
| Feb. 9, 2023 | Lorton Kenneth Patrick | EVP & Chief Technology Officer | A | Stock Option (right to buy) | 49000 | $0.00 | 49,000.0000 | 71,173,419 | 9999.99% | 0.07% |
| Feb. 9, 2023 | Herman Jenny | SVP & Controller | A | Common Stock | 8000 | $0.00 | 8,003.0000 | 71,173,419 | 9999.99% | 0.01% |
| Feb. 9, 2023 | Herman Jenny | SVP & Controller | A | Stock Option (right to buy) | 13000 | $0.00 | 13,000.0000 | 71,173,419 | 9999.99% | 0.02% |
| Feb. 9, 2023 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 84960 | $0.00 | 84,960.0000 | 71,173,419 | 9999.99% | 0.12% |
| Feb. 9, 2023 | Farid Ramy | President & CEO | A | Stock Option (right to buy) | 65525 | $0.00 | 65,525.0000 | 71,173,419 | 9999.99% | 0.09% |
| Feb. 9, 2023 | Akinsanya Karen | President of R&D, Therapeutics | A | Stock Option (right to buy) | 63270 | $0.00 | 63,270.0000 | 71,173,419 | 9999.99% | 0.09% |
| Feb. 9, 2023 | Abel Robert Lorne | See Remarks | A | Common Stock | 10545 | $0.00 | 10,545.0000 | 71,173,419 | 9999.99% | 0.01% |
| Feb. 2, 2023 | Tran Yvonne | EVP & Chief Legal Officer | M | Stock Option (right to buy) | 11731 | $2.92 | 0.0000 | 71,173,419 | 100.00% | 0.02% |
| Feb. 2, 2023 | Tran Yvonne | EVP & Chief Legal Officer | M | Common Stock | 13269 | $3.07 | 30,131.0000 | 71,173,419 | 78.69% | 0.02% |
| Feb. 2, 2023 | Tran Yvonne | EVP & Chief Legal Officer | M | Common Stock | 11731 | $2.92 | 16,862.0000 | 71,173,419 | 228.63% | 0.02% |
| Feb. 2, 2023 | Tran Yvonne | EVP & Chief Legal Officer | M | Stock Option (right to buy) | 13269 | $3.07 | 108.0000 | 71,173,419 | 99.19% | 0.02% |
| Feb. 2, 2023 | Tran Yvonne | EVP & Chief Legal Officer | S | Common Stock | 25000 | $27.26 | 5,131.0000 | 71,173,419 | 82.97% | 0.04% |
| Jan. 4, 2023 | Farid Ramy | President & CEO | S | Common Stock | 66886 | $18.28 | 184,432.0000 | 71,173,419 | 26.61% | 0.09% |
| Jan. 4, 2023 | Farid Ramy | President & CEO | M | Stock Option (right to buy) | 66886 | $0.00 | 0.0000 | 71,173,419 | 100.00% | 0.09% |
| Jan. 4, 2023 | Farid Ramy | President & CEO | M | Common Stock | 66886 | $1.20 | 251,318.0000 | 71,173,419 | 36.27% | 0.09% |